CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.02B, above the global median of $1.18B
- FinancialsAltman Z-Score 1.59: grey zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.02BUSDvs all stocks (USD)
Revenue (TTM)
169.90MUSDvs all stocks (USD)
Profit Margin
-88.19%vs Biotechnology peers
Beta
1.53xvs all stocks
52-Week Change
78.26%vs all stocks
Market Capitalization
2.02BUSDvs all stocks (USD)
Enterprise Value
1.77BUSDvs all stocks (USD)
Forward P/E
-382.67xvs Biotechnology peers
Price to Sales (TTM)
11.86xvs Biotechnology peers
Price to Book (MRQ)
7.91xvs Biotechnology peers
Enterprise to Revenue
10.42xvs Biotechnology peers
Enterprise to EBITDA
-13.07xvs Biotechnology peers
Gross Margin
70.11%vs Biotechnology peers
Profit Margin
-88.19%vs Biotechnology peers
Operating Margin
-161.06%vs Biotechnology peers
Return on Assets (TTM)
-12.36%vs Biotechnology peers
Return on Equity (TTM)
-47.81%vs Biotechnology peers
Revenue (TTM)
169.90MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4970USDUpdated Sep 28, 2026Quarterly Revenue Growth
555.60%vs Biotechnology peers
Gross Profit (TTM)
149.81MUSDvs all stocks (USD)
EBITDA (TTM)
-135.48MUSDvs all stocks (USD)
Net Income (TTM)
-149.83MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
555.64%vs Biotechnology peers
Operating Cash Flow (TTM)
-120.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-112.11MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
62.90MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
9.30MUSDFY2025 · Dec 31, 2025Gross Profit
53.60MUSDFY2025 · Dec 31, 2025Operating Income
-213.06MUSDvs all stocks (USD)
Pre-tax Income
-204.63MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-204.63MUSDFY2025 · Dec 31, 2025EBIT
-190.94MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-188.37MUSDFY2025 · Dec 31, 2025Research & Development
115.11MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
151.56MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
21.43MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
13.68MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-204.63MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-175.98MUSDFY2025 · Dec 31, 2025Free Cash Flow
-176.34MUSDDerived from operating cash flow minus capital expenditure. This filing charges 1.74M of depreciation against 354K of capital expenditure, and its own free-cash-flow line reads -181.78M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
164.09MUSDFY2025 · Dec 31, 2025Income Tax Paid
197.00KUSDFY2025 · Dec 31, 2025Interest Paid
2.88MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-204.63MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.74MUSDFY2025 · Dec 31, 2025Stock-based Compensation
35.89MUSDFY2025 · Dec 31, 2025Other Non-cash Items
11.07MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.07MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.13MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.13MUSDFY2025 · Dec 31, 2025Capital Expenditures
-354.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-8.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-354.42MUSDFY2025 · Dec 31, 2025Sale of Investments
462.29MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
107.52MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-11.90MUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
48.20MUSDFY2025 · Dec 31, 2025Other Financing Charges
142.91MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
179.22MUSDFY2025 · Dec 31, 2025Shares Outstanding
349.82MSharesUpdated Sep 28, 2026Float Shares
263.65MSharesUpdated Sep 28, 2026Shares Short
58.17MSharesUpdated Sep 28, 2026Short Ratio
11.17daysvs all stocks
Short % of Shares Outstanding
27.28%vs all stocks
% Held by Insiders
18.44%vs all stocks
% Held by Institutions
67.97%vs all stocks
Total Cash (MRQ)
660.96MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.88USDUpdated Sep 28, 2026Total Debt (MRQ)
416.26MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.64xvs Biotechnology peers
Current Ratio (MRQ)
8.37xvs Biotechnology peers
Book Value per Share (MRQ)
0.7260USDUpdated Sep 28, 2026Total Assets
594.82MUSDvs all stocks (USD)
Total Current Assets
571.52MUSDFY2025 · Dec 31, 2025Total Liabilities
289.11MUSDFY2025 · Dec 31, 2025Total Non-current Assets
23.30MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
206.88MUSDFY2025 · Dec 31, 2025Total Current Liabilities
82.23MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
164.09MUSDFY2025 · Dec 31, 2025Other Short-term Investments
365.13MUSDFY2025 · Dec 31, 2025Accounts Receivable
16.08MUSDFY2025 · Dec 31, 2025Inventory
11.41MUSDFY2025 · Dec 31, 2025Accounts Payable
9.48MUSDFY2025 · Dec 31, 2025Short-term Debt
7.60MUSDFY2025 · Dec 31, 2025Deferred Revenue
7.51MUSDFY2025 · Dec 31, 2025Other Current Liabilities
12.45MUSDFY2025 · Dec 31, 2025Long-term Debt
49.75MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
145.82MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.42BUSDFY2025 · Dec 31, 2025Retained Earnings
-1.12BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
305.72MUSDvs all stocks (USD)
52-Week Low
3.15USDUpdated Sep 28, 202652-Week High
9.75USDUpdated Sep 28, 202652-Week Change
78.26%vs all stocks
Beta
1.53xvs all stocks
50-Day MA
6.42USDUpdated Sep 28, 2026200-Day MA
5.86USDUpdated Sep 28, 2026Avg 10-Day Volume
5.05MSharesUpdated Sep 28, 2026Avg 30-Day Volume
5.20MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.4400USDUpdated Sep 28, 2026Other Income / Expense
689.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.70Profit Margin: -0.88
Significant cash reserves alongside high leverageNotable
Cash (USD): 660,956,032Total Debt (USD): 416,263,008Debt-to-Equity: 1.64
Financial Health
Altman Z-Score 1.59: grey zoneSignificant
Altman Z-Score: 1.59
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.02B, above the global median of $1.18BNotable
Market cap (USD): 2,015,447,357Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Sk Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mesoblast Limited
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Urogen Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inspire Medical Systems, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Galapagos NV
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Qingdao Eastsoft Communication Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Sunwoda Electronic Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Xianheng International Science And Technology Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline